Project Details
Goal of the project
P-PEAKS is a multicenter, intercontinental Phase II randomized controlled trial evaluating the safety, efficacy, and feasibility of personalized bacteriophage therapy in combination with intravenous beta-lactam antibiotics for the secondary prevention of recurrent urinary tract infections (rUTIs) caused by Escherichia coli in female patients. The project aims to deliver an improved, effective and meaningful solution for the prevention of recurrent UTIs in female patients improving their health outcomes and quality of life.
Role of the organisation
Partner beneficiary in charge of the phage production and testing.
Funding acknowledgement
This project is co-financed by the Horizon Europe program (Grant number: 101289070).
| Short title | Personalized-Phage Against E. Coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections |
|---|---|
| Acronym | P-PEAKS UTI |
| Status | Not started |
| Effective start/end date | 1/06/26 → 31/05/30 |
Collaborative partners
- Royal Military Academy
- Unity Health Toronto (lead)
- TARTU ULIKOOL
- HADASSAH MEDICAL ORGANIZATION
- Assistance Publique-Hôpitaux de Paris Centre Université-Paris
- FUNDACION PUBLICA GALEGA DE INVESTIGACION BIOMEDICA INIBIC
- The Hebrew University of Jerusalem
- University College London
- Lund University
- University of Calgary
- UNIVERSITE LAVAL
- Europaischer Nierenpatientenverband
- AZIENDA OSPEDALIERO UNIVERSITARIA PISANA
- Mayo Clinic
- FAGOTERAPIA LAB S.R.L.
- SIHTASUTUS TARTU ULIKOOLI KLIINIKUM
- BAYLOR COLLEGE OF MEDICINE
- PHILIPPS UNIVERSITAET MARBURG
- MICRON RESEARCH LIMITED
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- QEEN BIOTECHNOLOGIES INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.